Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (TRAVERSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03946072
Recruitment Status : Recruiting
First Posted : May 10, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).

Condition or disease Intervention/treatment Phase
Neurocognitive Dysfunction Procedure: Transseptal Aortic Approach Catheter Ablation Procedure Procedure: Retrograde Aortic Approach Catheter Ablation Procedure Not Applicable

Detailed Description:
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs). Participants will be followed for 6 months post-study procedure. This study will be conducted at up to 12 clinical sites in the United States. A total of one-hundred and fifty (150) participants will be enrolled and randomized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Multi-center Comparative Effectiveness RCT to Assess a Transseptal Approach to Left Ventricular Ablation Compared to a Retrograde Aortic Approach to Prevent Cerebral Emboli & Neurocognitive Decline in Adults With VT and/or PVCs
Actual Study Start Date : July 2, 2019
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : December 1, 2021

Arm Intervention/treatment
Active Comparator: Transseptal Group
Transseptal Aortic Approach Catheter Ablation Procedure
Procedure: Transseptal Aortic Approach Catheter Ablation Procedure
The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or RF device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.

Active Comparator: Retrograde Group
Retrograde Aortic Approach Catheter Ablation Procedure
Procedure: Retrograde Aortic Approach Catheter Ablation Procedure
The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.




Primary Outcome Measures :
  1. cerebral embolic lesion incidence [ Time Frame: on day 1 post-ablation ]
    incidence of new cerebral embolic lesions measured by magnetic resonance imaging (MRI) post-ablation as compared to pre-ablation imaging studies

  2. overall neurocognitive function, change [ Time Frame: from baseline (pre-ablation) to 6 months post-ablation ]
    percent change in overall neurocognitive function score from baseline (pre-ablation). The neurocognitive function examination includes items from the Brain Health Assessment, a validated, multi-domain testing battery aims to detect cognitive impairment in older adults. The TRAVERSE Testing Battery will include the following tests: Favorites (Forms A and B), Match (Forms A and B), Favorites Delay (Forms A and B), Favorites Recognition (Forms A and B), Dot Counting (Forms A and B), Flanker, and Running Dots.


Secondary Outcome Measures :
  1. new cerebral embolic lesions, number [ Time Frame: on day 1 post-ablation ]
    number of new cerebral embolic lesions per person, measured by magnetic resonance imaging (MRI) post-ablation as compared to pre-ablation imaging studies

  2. complications related to the ablation procedure, rate [ Time Frame: post-ablation, through Month 6 ]
    rate of complications related to the ablation procedure

  3. symptoms specific to VT/ PVC, change [ Time Frame: from pre-ablation to post-ablation, through Month 6 ]
    change in self-reported symptoms specific to VT/ PVC

  4. quality of life composite score, change [ Time Frame: from baseline (pre-ablation) to 6 months post-ablation ]
    change in quality of life score (composite summary points) measured using the Short Form 12-item Survey (SF-12), a validated measure of health status.

  5. physical activity (MET-min/week), change [ Time Frame: from baseline (pre-ablation) to 6 months post-ablation ]
    change in total physical activity (MET-min/week) measured using the International Physical Activity Questionnaire (IPAQ) short format questionnaire, validated for physical activity-related energy expenditure.

  6. recurrent arrhythmias, rate [ Time Frame: at 6 months post-ablation ]
    rate of recurrent arrhythmias determined as part of routine clinical care, measured using ECG and continuous ECG monitoring, if data is available



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Men and women ≥ 18 years of age
  2. Planned/scheduled endocardial ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure
  3. For this patient, the current plan of the operator must be to pursue a catheter ablation target in the left ventricular endocardium that can be accessed by either a transseptal puncture or retrograde aortic approach
  4. Life expectancy of at least 1 year
  5. Willing and able to undergo pre- and post-ablation MRIs
  6. Willing and able to return and comply with scheduled follow up visits (through the 6 month follow-up)
  7. Willing and able to provide written informed consent

Exclusion Criteria:

  1. Planned epicardial ablation that would include a coronary angiogram (during the index ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure)
  2. Any contraindication to MRI (as defined by the institution performing the MRI)
  3. Clinical contraindication to a retrograde aortic approach as determined by the treating physician, including:

    1. Severe Aortic stenosis
    2. Mechanical aortic valve
  4. Clinical contraindication to a transseptal puncture as determined by the treating physician , including:

    1. Severe Mitral valve stenosis
    2. Mechanical Mitral valve
    3. ASD or PFO closure device that would preclude a transseptal puncture
    4. Mitraclip or Alfieri mitral valve repair that would preclude a transseptal puncture
  5. Planned or known need to perform either a retrograde aortic approach or transseptal approach (such as to target another site during the same procedure)
  6. Inability to speak, read, and write in the English language at a 6th grade level (required for the Neurocognitive Function Testing)
  7. Current mental impairment or other diagnosis which precludes accurate assessment of neurocognitive function or which may not allow patient to understand the nature, significance and scope of the study
  8. Inability to perform neurocognitive function testing after > 24 hours free of sedating medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03946072


Contacts
Layout table for location contacts
Contact: Trisha F. Hue, PhD 415-476-2300 THue@psg.ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Gregory M Marcus, MD, MAS    415-476-5706    Greg.Marcus@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Gregory Marcus, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03946072    
Other Study ID Numbers: TRAVERSE
First Posted: May 10, 2019    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders